专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012053788A2 INJECTION NEEDLE FOR INJECTING CELL AND SYRINGE HAVING SAME 审中-公开
标题翻译：用于注射细胞的注射针和具有相同的注射针
公开(公告)号：WO2012053788A2
公开(公告)日：2012-04-26
申请号：PCT/KR2011007715
申请日：2011-10-17
申请人： BYUN KI HYUN , CHABIO & DIOSTECH CO LTD , CHUNG HYUNG MIN , MOON SUNG HWAN , HONG KI SUNG
发明人： BYUN KI HYUN , CHUNG HYUNG MIN , MOON SUNG HWAN , HONG KI SUNG
IPC分类号： A61M5/32 , A61M5/158 , A61M5/178
CPC分类号： A61M5/329 , A61M5/3291
摘要： The present invention relates to an injection needle and a syringe for injecting a stem cell inside a cardiac muscular tissue necrotic from a myocardial infarction or an ischemic heart failure, and the present invention provides an injection needle for injecting a cell, the injection needle having a needle shaft wound in a spiral shape. The injection needle and the syringe of the present invention prevent the cell sap from leaking outside the epicardium after being injected into the cardiac muscular tissue, and at the same time, enhance the survival rate of the stem cell inside the necrotic cardiac muscular tissue by resuming the circulation of the blood stream in the injected stem cell.
摘要翻译：本发明涉及一种注射针头和注射器，用于从心肌梗塞或缺血性心力衰竭中将坏死的坏死肌肉组织注入干细胞，本发明提供了一种用于注射细胞的注射针，所述注射针具有针轴缠绕成螺旋状。本发明的注射针和注射器在注入心肌组织后，可防止细胞液在外膜外泄漏，同时通过恢复，提高坏死心肌组织内的干细胞的存活率注射干细胞中血流的循环。

2. 发明申请

WO2011002200A3 NOVEL GUANOSINE-RICH MODIFIED OLIGONUCLEOTIDES AND ANTIPROLIFERATIVE ACTIVITY THEREOF 审中-公开
标题翻译：新型冠心病修饰寡核苷酸及其抗增殖活性
公开(公告)号：WO2011002200A3
公开(公告)日：2011-09-29
申请号：PCT/KR2010004202
申请日：2010-06-29
申请人： APTABIO THERAPEUTICS INC , LEE SOO JIN , MOON SUNG HWAN
发明人： LEE SOO JIN , MOON SUNG HWAN
IPC分类号： A61K31/7115 , C07H19/06 , A61P35/00 , C07H21/00 , C07H21/02 , C12N15/11
CPC分类号： C07H19/173 , C07H21/00
摘要： The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition having cell apoptotic activity against cancer cells for preventing or treating cancer comprising a guanosine-rich modified oligonucleotide with at least one therapeutically effective modified nucleic acid (N), or its pharmaceutically acceptable salt as active ingredient.
摘要翻译：本发明涉及包含至少一种鸟苷分子和具有治疗功效的经修饰的核酸的新型修饰寡核苷酸。本发明还涉及具有至少一种治疗有效的修饰核酸（N）或其药学上可接受的盐作为活性成分的具有用于预防或治疗癌症的癌细胞的细胞凋亡活性的药物组合物，其包含富含鸟嘌呤的修饰的寡核苷酸。

3. 发明申请

WO2011132904A2 APPARATUS AND METHOD FOR CONTROLLING POWER OF VEHICLE FOR CARRYING FROZEN, REFRIGERATED AND HEATED FOOD 审中-公开
标题翻译：控制冷冻，冷藏和加热食品车辆动力的装置和方法
公开(公告)号：WO2011132904A2
公开(公告)日：2011-10-27
申请号：PCT/KR2011002772
申请日：2011-04-19
申请人： C 1 CO LTD , KWAK JUNG BIN , KIM GYU NAM , MOON SUNG HWAN
发明人： KWAK JUNG BIN , KIM GYU NAM , MOON SUNG HWAN
IPC分类号： B60P3/20 , B60P3/00 , F25D19/00
CPC分类号： B60P3/20
摘要： The present invention relates to an apparatus and method for controlling the power of a vehicle for food storage, wherein: a main controller determines the power charged in a battery cell while adjusting the temperature of a food storage room to a preset temperature by controlling a temperature adjustment unit and a fan motor driving unit; the main controller controls a power supply source to supply alternating current power when the power charged in the battery cell, which has been determined, is equal to or less than a preset minimum power, wherein the supplied alternating current power is converted into direct current power by a direct current power conversion unit to be charged in the battery cell; and the main controller controls the power supply source to not supply alternating current power when the power charged in the battery cell, which has been determined, is equal to or greater than a preset maximum power.
摘要翻译：本发明涉及一种用于控制用于食品储存的车辆的动力的装置和方法，其中：主控制器通过控制温度来确定食物储藏室的温度到预设温度的同时在电池单元中充电的功率调整单元和风扇马达驱动单元; 主控制器控制供电源，以便在已经确定的电池单体中充电的电力等于或小于预设的最小功率时提供交流电力，其中所提供的交流电力被转换成直流电力通过直流电力转换单元来充电在电池单元中; 并且当已经确定的电池单元中充电的电力等于或大于预设的最大功率时，主控制器控制电源不能提供交流电力。

4. 发明申请

WO2011002200A2 NOVEL GUANOSINE-RICH MODIFIED OLIGONUCLEOTIDES AND ANTIPROLIFERATIVE ACTIVITY THEREOF 审中-公开
标题翻译：新型富含核糖核酸的修饰寡核苷酸及其抗增殖活性
公开(公告)号：WO2011002200A2
公开(公告)日：2011-01-06
申请号：PCT/KR2010/004202
申请日：2010-06-29
申请人： APTABIO THERAPEUTICS INC. , LEE, Soo Jin , MOON, Sung Hwan
发明人： LEE, Soo Jin , MOON, Sung Hwan
IPC分类号： C07H19/06
CPC分类号： C07H19/173 , C07H21/00
摘要： The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition having cell apoptotic activity against cancer cells for preventing or treating cancer comprising a guanosine-rich modified oligonucleotide with at least one therapeutically effective modified nucleic acid (N), or its pharmaceutically acceptable salt as active ingredient.
摘要翻译：本发明涉及新的修饰的寡核苷酸，其包含至少一个鸟苷分子和具有治疗功效的修饰的核酸。本发明还涉及用于预防或治疗癌症的具有细胞凋亡活性的药物组合物，其包含富含鸟苷的修饰的寡核苷酸和至少一种治疗有效的修饰的核酸（N）或其药学上可接受的盐作为活性成分。

5. 发明申请

WO2009035217A1 PROCESS FOR DIFFERENTIATION OF VASCULAR ENDOTHELIAL PROGENITOR CELLS FROM EMBRYOID BODIES DERIVED FROM EMBRYONIC STEM CELLS USING HYPOXIC MEDIA CONDITION 审中-公开
标题翻译：使用HYPOXIC MEDIA CONDITION从胚胎干细胞衍生的EMBRYOID体中分离血管内皮祖细胞的方法
公开(公告)号：WO2009035217A1
公开(公告)日：2009-03-19
申请号：PCT/KR2008/004723
申请日：2008-08-14
申请人： CHABIOTECH CO., LTD. , CHUNG, Hyung-Min , KIM, Ju-Mi , LEE, Soo-Hong , MOON, Sung-Hwan
发明人： CHUNG, Hyung-Min , KIM, Ju-Mi , LEE, Soo-Hong , MOON, Sung-Hwan
IPC分类号： C12N5/08
CPC分类号： C12N5/0691 , C12N2500/02 , C12N2506/02
摘要： The present invention provides a process for differentiation of vascular endothelial progenitor cells from embryoid bodies derived from embryonic stem cells, the process comprising: (a) treating a culture medium comprising embryoid bodies derived from embryonic stem cells such that the concentration of oxygen dissolved in the culture medium is in the range of about 1 ppm to about 5 ppm; (b) culturing the culture medium prepared in step (a) in an incubator in which the oxygen (O 2 ) tension is equal to or less than about 15 % to differentiate the embryoid bodies into vascular endothelial progenitor cells; and (c) isolating the vascular endothelial progenitor cells from the culture medium obtained in step (b).
摘要翻译：本发明提供从源自胚胎干细胞的胚状体分化血管内皮祖细胞的方法，该方法包括：（a）处理包含来源于胚胎干细胞的胚状体的培养基，使得溶于培养基在约1ppm至约5ppm的范围内; （b）在氧（O 2）张力等于或小于约15％的培养箱中培养步骤（a）中制备的培养基，以将胚状体分化成血管内皮祖细胞; 和（c）从步骤（b）中获得的培养基中分离血管内皮祖细胞。

6. 发明申请

WO2008153231A1 PROCESS FOR ISOLATING VASCULAR ENDOTHELIAL CELLS FROM EMBRYOID BODIES DIFFERENTIATED FROM EMBRYONIC STEM CELLS 审中-公开
标题翻译：从胚胎干细胞分化的EMBRYOID体内分离血管内皮细胞的方法
公开(公告)号：WO2008153231A1
公开(公告)日：2008-12-18
申请号：PCT/KR2007/002840
申请日：2007-06-13
申请人： CHABIOTECH CO., LTD. , COLLEGE OF MEDICINE POCHON CHA UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION , CHUNG, Hyung-Min , MOON, Sung-Hwan , KIM, Ju-Mi , LEE, Soo-Hong
发明人： CHUNG, Hyung-Min , MOON, Sung-Hwan , KIM, Ju-Mi , LEE, Soo-Hong
IPC分类号： C12N5/06 , C12N5/08 , C12N5/02 , C12N5/00
CPC分类号： C12N5/069 , C12N2506/02 , C12N2509/00
摘要： The present invention provides a process for isolating vascular endothelial cells from embryoid bodies differentiated from embryonic stem cells, which comprises: (a) treating embryoid bodies differentiated from embryonic stem cells with 0.005 - 0.015% trypsin and 0.05 - 0.15 mM ethylenediaminetetraacetate (EDTA) to obtain vascular endothelial cell clusters; and (b) treating the vascular endothelial cell clusters with 0.1 - 0.5% trypsin and 0.5 - 2 mM EDTA so as to separate the vascular endothelial cell clusters into single cells.
摘要翻译：本发明提供了从胚胎干细胞分化的胚状体分离血管内皮细胞的方法，其包括：（a）用0.005-0.015％胰蛋白酶和0.05-0.15mM乙二胺四乙酸（EDTA）处理从胚胎干细胞分化的胚状体，以获得血管内皮细胞簇; 和（b）用0.1-0.5％胰蛋白酶和0.5-2mM EDTA处理血管内皮细胞簇，以将血管内皮细胞簇分离为单个细胞。

7. 发明申请

WO2005116032A2 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO 审中-公开
标题翻译：反转模拟法和与之相关的方法
公开(公告)号：WO2005116032A2
公开(公告)日：2005-12-08
申请号：PCT/US2005/012799
申请日：2005-04-15
申请人： CHOONGWAE PHARMA CORPORATION , MOON, Sung Hwan , CHUNG, Jae Uk , LEE, Sung Chan , EGUCHI, Masakatsu , KAHN, Michael , JEONG, Kwang Won , NGUYEN, Cu , LEE, Soo Jin
发明人： MOON, Sung Hwan , CHUNG, Jae Uk , LEE, Sung Chan , EGUCHI, Masakatsu , KAHN, Michael , JEONG, Kwang Won , NGUYEN, Cu , LEE, Soo Jin
IPC分类号： C07D487/00
CPC分类号： C07D487/04 , A61K31/4985 , Y02A50/467
摘要： Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
摘要翻译：公开了模拟生物活性肽和蛋白质的逆转区二级结构的构象约束化合物。这种反转模拟结构可用于广泛的领域，包括用作诊断剂和治疗剂。还公开了含有本发明的反向模拟结构的文库以及筛选它们以鉴定生物活性成员的方法。本发明还涉及这些化合物用于抑制或治疗由Wnt信号传导途径调节的疾病，例如癌症，特别是结肠直肠癌，与血管成形术相关的再狭窄，多囊肾病，异常血管生成疾病，类风湿性关节炎疾病，结节性硬化症复合体，阿尔茨海默病，过多的头发生长或脱落，或溃疡性结肠炎。

8. 发明申请

WO2004108731A1 BETA-STRAND MIMETICS AND METHOD RELATING THERETO 审中-公开
标题翻译： BETA-STRAND的MIME类型和方法相关
公开(公告)号：WO2004108731A1
公开(公告)日：2004-12-16
申请号：PCT/US2003/017188
申请日：2003-05-30
申请人： CHOONGWAE PHARMA CORPORATION , KAHN, Michael , MASAKATSU, Eguchi , MOON, Sung, Hwan , CHUNG, Jae, Uk
发明人： KAHN, Michael , MASAKATSU, Eguchi , MOON, Sung, Hwan , CHUNG, Jae, Uk
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： Conformationally constrained compounds which mimic the secondary structure of ß-strand regions of biologically active peptides and proteins are disclosed. Such ß-strand mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the ß-strand mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members.
摘要翻译：公开了模拟生物活性肽和蛋白质的β链区域的二级结构的构象约束化合物。这种β链模拟结构在广泛的领域中具有实用性，包括用作诊断和治疗剂。还公开了含有本发明的β-链模拟结构的文库以及用于筛选本发明的鉴定生物活性成员的方法。

9. 发明申请

WO2004093828A2 REVERSE-TURN MIMETICS AND METHOD RELATING THERETO 审中-公开
标题翻译：反向转换和相关的方法
公开(公告)号：WO2004093828A2
公开(公告)日：2004-11-04
申请号：PCT/US2004/008270
申请日：2004-03-17
申请人： CHOONGWAE PHARMA CORPORATION , MOON, Sung-Hwan , CHUNG, Jae-Uk , LEE, Sung-Chan , EGUCHI, Masakatsu , KAHN, Michael , JEONG, Kwang-Won , NGUYEN, Cu
发明人： MOON, Sung-Hwan , CHUNG, Jae-Uk , LEE, Sung-Chan , EGUCHI, Masakatsu , KAHN, Michael , JEONG, Kwang-Won , NGUYEN, Cu
IPC分类号： A61K
CPC分类号： C07D487/04 , A61K31/5513 , A61K45/06 , C07D231/12 , C07D233/56 , C07D249/08 , C40B30/04 , C40B40/04 , C40B50/14 , A61K2300/00
摘要： Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.
摘要翻译：公开了模拟生物活性肽和蛋白质的反转转区的二级结构的构象约束化合物。这种反转模拟结构在广泛的领域中具有实用性，包括用作诊断和治疗剂。还公开了包含本发明的反转模拟结构的文库以及用于筛选其的方法以鉴定生物活性成员。本发明还涉及这种化合物用于抑制或治疗由Wnt信号传导途径调节的疾病，例如癌症，特别是结肠直肠癌，与血管成形术，多囊肾病，异常血管生成疾病，类风湿性关节炎疾病，结节性硬化综合征相关的再狭窄，阿尔茨海默氏病，过度毛发生长或损失，或溃疡性结肠炎。

10. 发明申请

WO2013036032A1 A PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING INTERFERON ALPHA CONJUGATE 审中-公开
标题翻译：用于治疗癌症的药物组合物，包括干扰素ALPHA联合
公开(公告)号：WO2013036032A1
公开(公告)日：2013-03-14
申请号：PCT/KR2012/007113
申请日：2012-09-05
申请人： HANMI SCIENCE CO., LTD. , BEIJING HANMI PHARMACEUTICAL CO., LTD. , JUNG, Sung Youb , WOO, Young Eun , LIM, Se Young , CHOI, In Young , LEE, Jae Ho , KWON, Se Chang , MOON, Sung Hwan , LIU, Jiawang
发明人： JUNG, Sung Youb , WOO, Young Eun , LIM, Se Young , CHOI, In Young , LEE, Jae Ho , KWON, Se Chang , MOON, Sung Hwan , LIU, Jiawang
IPC分类号： A61K38/21 , A61K39/395 , A61K47/48 , A61K47/30 , A61P35/00
CPC分类号： A61K47/642 , A61K9/0019 , A61K31/7068 , A61K38/212 , A61K47/60 , A61K47/68
摘要： The present invention relates to an anti-cancer pharmaceutical composition comprising an interferon alpha or a polymer congugate thereof and use thereof in the treatment of cancer by co-administration with anti-cancer agents. The interferon alpha conjugate of the present invention shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition of the present invention has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.
摘要翻译：本发明涉及包含干扰素α或其聚合物结合物的抗癌药物组合物及其在通过与抗癌药物共同给药治疗癌症中的用途。本发明的干扰素α结合物比常规的干扰素α显示出更长的体内半衰期和更优异的抗癌活性，特别是与抗癌药如吉西他滨的共同给药具有协同抑制作用对癌细胞生长和增殖的影响，以显示非常优异的抗癌活性。此外，本发明的抗癌药物组合物具有优异的体内半衰期和抗癌活性，从而大大降低给药频率。共同施用抗癌剂和具有优异抗癌活性的干扰素α缀合物降低了抗癌剂的施用剂量，从而降低了抗癌剂的副作用并增加了患者的治疗依从性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式